Alberto Verlicchi

832 total citations
25 papers, 421 citations indexed

About

Alberto Verlicchi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Alberto Verlicchi has authored 25 papers receiving a total of 421 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Alberto Verlicchi's work include Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). Alberto Verlicchi is often cited by papers focused on Lung Cancer Treatments and Mutations (17 papers), Lung Cancer Research Studies (6 papers) and Cancer Genomics and Diagnostics (5 papers). Alberto Verlicchi collaborates with scholars based in Italy, Spain and China. Alberto Verlicchi's co-authors include Rafael Rosell, Jordi Codony‐Servat, Angelo Delmonte, Lucio Crinò, Paola Ulivi, Giuseppe Bronte, Paola Cravero, Maximilian Papi, Niki Karachaliou and Elisa Chiadini and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Frontiers in Immunology.

In The Last Decade

Alberto Verlicchi

21 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alberto Verlicchi Italy 12 268 228 175 120 37 25 421
Germira Di Gioia Italy 7 174 0.6× 188 0.8× 151 0.9× 127 1.1× 58 1.6× 7 391
Santino Minichillo Italy 9 160 0.6× 120 0.5× 84 0.5× 137 1.1× 25 0.7× 17 347
Jolanta Szade Poland 12 266 1.0× 78 0.3× 143 0.8× 151 1.3× 27 0.7× 32 406
C. Lance Cowey United States 7 119 0.4× 141 0.6× 193 1.1× 113 0.9× 19 0.5× 11 313
Saravut J. Weroha United States 8 136 0.5× 94 0.4× 223 1.3× 85 0.7× 15 0.4× 19 349
Ngoc T. Hoang United States 6 155 0.6× 200 0.9× 274 1.6× 130 1.1× 10 0.3× 8 467
Tongmei Zhang China 11 219 0.8× 96 0.4× 138 0.8× 123 1.0× 32 0.9× 49 389
Xiangli Jiang China 14 171 0.6× 171 0.8× 307 1.8× 222 1.9× 15 0.4× 23 512
Maria Saigí Spain 10 172 0.6× 142 0.6× 203 1.2× 104 0.9× 32 0.9× 24 380
Xin-Jun Dong China 8 164 0.6× 96 0.4× 297 1.7× 72 0.6× 18 0.5× 12 418

Countries citing papers authored by Alberto Verlicchi

Since Specialization
Citations

This map shows the geographic impact of Alberto Verlicchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Verlicchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Verlicchi more than expected).

Fields of papers citing papers by Alberto Verlicchi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Verlicchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Verlicchi. The network helps show where Alberto Verlicchi may publish in the future.

Co-authorship network of co-authors of Alberto Verlicchi

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Verlicchi. A scholar is included among the top collaborators of Alberto Verlicchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Verlicchi. Alberto Verlicchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Canale, Matteo, Eugenio Fonzi, Letizia Gnetti, et al.. (2025). Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients. PubMed. Volume 16. 85–96. 1 indexed citations
2.
Foca, Flavia, Mattia Altini, Angelo Delmonte, et al.. (2024). Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients. Cancers. 16(3). 592–592. 1 indexed citations
3.
Bertolini, Federica, Elisabetta Petracci, Stefania Bettelli, et al.. (2023). Genomic profiling in advanced NSCLC in Italy: First results of NERoNE (NSCLC Emilia Romagna Next Generation Sequencing Evaluation) project.. Journal of Clinical Oncology. 41(16_suppl). e21077–e21077.
4.
Verlicchi, Alberto, Matteo Canale, Elisa Chiadini, et al.. (2023). The Clinical Significance of Circulating Tumor DNA for Minimal Residual Disease Identification in Early-Stage Non-Small Cell Lung Cancer. Life. 13(9). 1915–1915. 1 indexed citations
5.
Andrikou, Kalliopi, Tania Rossi, Alberto Verlicchi, et al.. (2023). Circulating Tumour Cells: Detection and Application in Advanced Non-Small Cell Lung Cancer. International Journal of Molecular Sciences. 24(22). 16085–16085. 14 indexed citations
6.
Bronte, Giuseppe, Alberto Verlicchi, Serena De Matteis, et al.. (2021). Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors. Frontiers in Immunology. 12. 672219–672219. 3 indexed citations
7.
Bronte, Giuseppe, Angelo Delmonte, Marco Angelo Burgio, et al.. (2020). Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement. Lung Cancer. 142. 47–50. 9 indexed citations
8.
Canale, Matteo, Elisabetta Petracci, Angelo Delmonte, et al.. (2020). Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs. Journal of Clinical Medicine. 9(4). 1047–1047. 52 indexed citations
9.
Bronte, Giuseppe, Paola Ulivi, Alberto Verlicchi, et al.. (2019). <p>Targeting RET-rearranged non-small-cell lung cancer: future prospects</p>. PubMed. Volume 10. 27–36. 46 indexed citations
10.
Delmonte, Angelo, Marco Angelo Burgio, Alberto Verlicchi, et al.. (2019). New generation anaplastic lymphoma kinase inhibitors. Translational Lung Cancer Research. 8(S3). S280–S289. 13 indexed citations
11.
Matteis, Serena De, Matteo Canale, Alberto Verlicchi, et al.. (2019). Advances in Molecular Mechanisms and Immunotherapy Involving the Immune Cell-Promoted Epithelial-to-Mesenchymal Transition in Lung Cancer. Journal of Oncology. 2019. 1–11. 19 indexed citations
12.
Ito, Masaoki, Carles Codony, Jordi Codony‐Servat, et al.. (2019). Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Communication and Signaling. 17(1). 137–137. 35 indexed citations
13.
Rosell, Rafael, Imane Chaib, Niki Karachaliou, et al.. (2017). OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer. Journal of Thoracic Oncology. 12(1). S281–S282. 1 indexed citations
14.
Verlicchi, Alberto, Niki Karachaliou, Chiara Lazzari, et al.. (2017). P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma. Journal of Thoracic Oncology. 12(1). S1143–S1143.
15.
Dazzi, Claudio, Alessandro Gamboni, Angelo Delmonte, et al.. (2017). Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study.. Journal of Clinical Oncology. 35(15_suppl). e20676–e20676.
16.
Verlicchi, Alberto, Niki Karachaliou, Chiara Lazzari, et al.. (2016). 72P Differential expression profile of lung squamous cell carcinoma (LSCC) cell lines as a mean to predict drug interaction effects. Journal of Thoracic Oncology. 11(4). S85–S86. 1 indexed citations
17.
Karachaliou, Niki, Chiara Lazzari, Alberto Verlicchi, Aaron E. Sosa, & Rafael Rosell. (2016). HER3 as a Therapeutic Target in Cancer. BioDrugs. 31(1). 63–73. 25 indexed citations
18.
Ulivi, Paola, Elisa Chiadini, Claudio Dazzi, et al.. (2015). Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy. Clinical Lung Cancer. 17(5). 384–390. 75 indexed citations
19.
20.
Dazzi, Claudio, Anna Cariello, Cláudia Casanova, et al.. (2012). Gemcitabine and Paclitaxel Combination as Second-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Phase II Study. Clinical Lung Cancer. 14(1). 28–33. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Germira Di Gioia Breakdown of academic impact, for papers by Santino Minichillo Breakdown of academic impact, for papers by Jolanta Szade Breakdown of academic impact, for papers by C. Lance Cowey Breakdown of academic impact, for papers by Saravut J. Weroha Breakdown of academic impact, for papers by Ngoc T. Hoang Breakdown of academic impact, for papers by Tongmei Zhang Breakdown of academic impact, for papers by Xiangli Jiang Breakdown of academic impact, for papers by Maria Saigí Breakdown of academic impact, for papers by Xin-Jun Dong
Rankless by CCL
2026